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Cardiovascular disease in pediatric chronic dialysis patients. Little has been written about cardiovascular-associ-
Background. Little information is available regarding car- ated morbidity and mortality in the pediatric end-stage
diac morbidity and mortality in children with end-stage renal dis- renal disease (ESRD) patient. It is not known how manyease. We sought to determine the incidence of cardiac morbid-
pediatric ESRD patients have established cardiac abnor-ity and mortality in pediatric chronic dialysis patients.
malities when they begin dialysis, or if there is variance byMethods. Medicare incident pediatric (0 to 19 years) dialysis
patients from 1991 to 1996 were identified from the United the type of treatment modality. Large studies assessing po-
States Renal Data System. Study endpoints included develop- tential risk factors for cardiovascular morbidity and mor-
ment of arrhythmia, valvular heart disease, cardiomyopathy, or
tality have not been performed in children with ESRD.cardiac arrest, all causes of death, and cardiac-related death.
Yet risk factors for cardiovascular mortality such as hy-Statistical analyses were performed using the Poisson regres-
sion model and chi-square test. pertension, left ventricular hypertrophy, and left ventric-
Results. A total of 1454 children were eligible for inclusion, ular dysfunction have been described in children under-
452 (31.1%) of whom developed a cardiac-related event. Ar- going chronic dialysis therapy [7–10]. Although elevatedrhythmia was the most common event (19.6%) compared with
lipid levels have been reported in children with chronicvalvular disease (11.7%), cardiomyopathy (9.6%), and cardiac
renal disease and may act in concert with hypertension toarrest (3%). Arrhythmia and valvular heart disease incidence
were increased in 15- to 19-year-olds (P  0.0001 for both), promote atherosclerosis, pediatric ESRD patients are
females (P  0.004, P  0.03) and blacks (P  0.0001, P  rarely monitored for hyperlipidemia [11, 12]. In two small
0.002). Cardiomyopathy incidence was increased in blacks (P
studies of pediatric and young adult dialysis populations,0.001) and tended to be increased in females (P  0.053). The
a high incidence of left ventricular hypertrophy [13] andadjusted annual cardiomyopathy rate during the first 3 years
increased between 1991 and 1996 (P  0.003). Death occurred coronary artery calcification [14] was detected. We used
in 107 patients, and 41 (38%) were cardiac deaths. the large USRDS database to examine the incidence
Conclusions. Cardiovascular disease is a significant cause of and extent of cardiovascular disease in US children onmorbidity and mortality in pediatric chronic dialysis patients.
chronic dialysis.Cardiomyopathy incidence is increasing. Black, female, and ado-
lescent children have increased risk for cardiovascular disease.
METHODS
We retrospectively analyzed data on children who be-Cardiovascular disease is the leading cause of patient
gan dialysis for ESRD from 1991 to 1996 for the extentdeaths among adults in the United States Renal Data Sys-
and incidence of cardiovascular disease as reported to thetem (USRDS) database, accounting for more than 40%
USRDS database. The accuracy of these data has beenof these deaths [1]. Risk factors associated with cardio-
previously validated [15]. Endpoints under study includedvascular mortality in adult dialysis patients include older
all causes of death, cardiac-related death (excluding deathsage, diabetes, hypertension, left ventricular hypertrophy,
associated with hyperkalemia), development of arrhyth-left ventricular dysfunction, hypoalbuminemia, and hy-
mia, development of cardiac arrest, development of val-perlipidemia [2–5]. A task force convened by the Na-
vular heart disease, and development of cardiomyopathy.tional Kidney Foundation in 1997 targeted the identifi-
Patients identified were those with code 394.X, 395.X,cation and treatment of coronary artery disease and left
ventricular hypertrophy as potential methods of reducing 396.X, 397.0, 424.0, 424.1, 424.2, 424.3, 425.X, 426.X,
cardiovascular mortality in adult patients with chronic 427.X, or 427.5 of the International Classification of Dis-
renal disease [6]. eases, Ninth Revision, Clinical Modification (ICD-9-
CM) [16]. The patient population included all children
younger than 20 years old who survived at least 90 daysKey words: cardiovascular disease, children, dialysis, end-stage renal
disease, heart, adolescents and HD. after starting dialysis and who were Medicare eligible at
day 90 after the first day of ESRD service. Each cohort 2002 by the International Society of Nephrology
648
Chavers et al: Cardiovascular disease in pediatric dialysis 649
Table 1. Patient demographics (incident dialysis years 1991–1996)was followed from day 91 of ESRD to December 31,
1998. A study endpoint was documented the first time it 1991 1992 1993 1994 1995 1996 Total
appeared in the part A or part B claims diagnosis codes. Age
0–4 40 30 32 27 40 37 206Patients were excluded from the analysis if they under-
5–9 25 24 21 30 20 23 143went transplantation but returned to dialysis within 90
10–14 60 55 48 44 48 59 314
days after the first day of ESRD service. Patient demo- 15–19 124 137 134 142 25 129 791
Racegraphic data included age, sex, race or ethnic group, and
White 152 151 145 153 124 129 854primary cause of ESRD. Primary renal diagnoses were
Black 79 77 77 75 71 90 469
grouped into four categories: glomerulonephritis, struc- Others 18 18 13 15 38 29 131
Gendertural abnormalities, hypertension, and other.
Female 107 122 102 117 97 111 656The Poisson regression model was used to compute
Male 142 124 133 126 136 137 798
the annual event rate in the first three years, adjusted for Primary diagnosis
GN 112 117 120 119 110 108 686age, sex, race, and ESRD diagnosis under the assumption
Structural 67 67 60 50 63 64 371of a constant incident rate for each incident cohort within
Hypertension 19 12 22 25 8 21 107
the follow-up period [17, 18]. The model can be stated Others 51 50 33 49 52 55 290
Totals 249 246 235 243 233 248 1454as  (X)  exp(X), where  represents the event rate
(events per patient-time) and the covariates X in the GN is glomerulonephritis.
model are: (1) age (continuous variable); (2) race (three-
level categorical variable: white, black, and other minor-
ity race); (3) gender (two-level: male and female); (4)
diac-related events varied significantly by age groupprimary cause of ESRD (four-level: glomerulonephritis,
(P  0.0001) and was 24.3% in 0- to 4-year-olds, 24.5%structural, hypertension, and others); (5) year (six-level:
in 5- to 9-year-olds, 23.9% in 10- to 14-year-olds, and1991 to 1996 incident cohorts); and (6) period (two-level:
36.9% in 15- to 19-year-olds. Females had a higher inci-first 3 years and after 3 years). The follow-up year was
dence of cardiac events (35.1% vs. 27.8% in males, P based on the patient year instead of the calendar year.
0.003) as did blacks (41.4% vs. 25.8% in whites and 29%Censoring occurred at transplantation, loss to follow-
in others, P 0.0001). Arrhythmia was the most commonup, death, and end of study. Patients were on dialysis
cardiac-related event (19.6%) followed by valvular hearttreatment for at least 90 days. The 2 test was used to
disease (11.7%), cardiomyopathy (9.6%), cardiac arresttest for significant differences for cardiovascular disease
(3.0%), and cardiac death (2.8%).incidence among the demographic groups (gender, race,
sex, ESRD diagnosis) at a significance level of 0.05. Cardiac disease by age group
The type of cardiac-related event differed significantly
RESULTS among age groups (Fig. 1) [19]. Arrhythmia occurred in
25% of patients in the 15 to 19 year age group comparedThe total number of incident pediatric dialysis patients
from 1991 to 1996 who did not receive renal transplanta- to 15% in the 10 to 14 age group, 9% in the 5 to 9 age
group, and 14% in the 0 to 4 age group (P  0.0001).tion within 90 days and who were Medicare eligible at
day 90 since beginning ESRD treatment was 1454. Pa- Valvular heart disease occurred in 15% of 15- to 19-year-
olds, 7% of 10- to 14-year-olds, 10% of 5- to 9-year-olds,tient demographics are shown in Table 1. The mean
patient age was 13 years (range 0 to 19 years); 14.2% and 6% of 0- to 4-year-olds (P  0.0001). Cardiac arrest
occurred in 5% of 0- to 4-year-olds, 0% of 5- to 9-year-were aged 0 to 4 years, 9.8% were 5 to 9, 21.6% were
10 to 14, and 54.4% were 15 to 19 [19]. Fifty-five percent olds, 2% of 10- to 14-year-olds, and 3% of 15- 19-year-
olds (P  0.02). There was no significant difference inof patients were male and 45% were female, while 58.7%
were white, 32.3% black, and 9.0% other. Forty-seven the incidence of cardiomyopathy based on patient age.
Cardiomyopathy occurred in 10% of 0- to 4-year-olds,percent had ESRD due to glomerulonephritis, 25.5%
to structural abnormalities, 7.4% to hypertension, and 11% of 5- to 9- and 15- to 19-year-olds, and 6% of 10-
to 14-year-olds.19.9% to other causes [19].
Overall cardiac-related events Cardiac disease by gender
The type of cardiac-related event differed significantlyOverall, 452 (31.1%) patients developed a cardiac-
related event. The number of patients developing events by gender [19]. Arrhythmia developed in 23% of girls
compared to 17% of boys (P  0.004). Valvular hearttended to vary by incident dialysis year (year in which
dialysis was started: 60 in 1991, 78 in 1992, 73 in 1993, disease occurred in 14% of girls and 10% of boys (P 
0.03). Cardiomyopathy tended to be increased in girls82 in 1994, 78 in 1995, 81 in 1996), but this did not achieve
statistical significance (P  NS). The incidence of car- (11%) compared to boys (8%; P  0.053). There was
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Fig. 1. Incidence of cardiovascular disease in
pediatric chronic dialysis patients by age group.
Symbols are: ( ) 0 to 4; ( ) 5 to 9; () 10 to
14; () 15 to 19.
Fig. 2. Incidence of cardiovascular disease in
pediatric chronic dialysis patients by race. Sym-
bols are: ( ) white; () black; () others.
Table 2. Adjusted annual cardiac events/1000 patient-yearsno significant difference in the incidence of cardiac arrest
in pediatric chronic dialysis patients
based on gender (2.8% girls vs. 3.2% boys).
Incident dialysis year
Cardiac disease by race Event 1991 1992 1993 1994 1995 1996 Trend
The type of cardiac-related event differed significantly Arrhythmia 90.9 115.0 138.9 145.0 141.3 128.6 P  NS
Cardiac arrest 19.1 18.0 10.0 19.5 11.6 22.0 P  NSamong racial groups (Fig. 2) [19]. Arrhythmia developed
Valvular disease 59.3 66.3 55.4 91.2 79.6 68.1 P  NSin 27% of blacks compared to 16% of whites and 17% Cardiomyo-
of others (P 0.0001). Valvular heart disease developed pathy 42.0 44.9 50.9 60.7 73.8 84.8 P  0.003
All-cause death 56.9 30.7 31.1 48.1 32.2 31.4 P  NSin 16% of blacks, 9.5% of whites, and 11% of others (P
Cardiac death 14.4 10.4 12.6 18.1 12.4 4.5 P  NS0.002). Cardiomyopathy was about twice as common in
blacks (14%) compared to whites (7.5%), and others
(8.4%; P  0.001). Although cardiac arrest occurred
twice as often in blacks (4.3%) compared to whites (2.3%) doubling from 42/1000 patient-years in 1991 to 84.8/1000
and others (2.3%), this difference was not statistically patient-years in 1996 (P  0.003, Fig. 3). Although car-
significant. diac arrest rates increased from 11.6/1000 patient-years
in 1995 to 22.0/1000 patient-years in 1996, this difference
Adjusted annual cardiac event rates did not achieve statistical significance.
After adjustment for age, sex, race, and primary ESRD
Overall and cardiac-related mortalitydiagnosis, no significant trends in annual event rates dur-
ing the first three years were noted for arrhythmia, valvu- The adjusted annual mortality rate from all causes and
lar heart disease or cardiac arrest (Table 2). The adjusted the cardiac-related mortality rate were 38.4/1000 patient-
years and 13.7/1000 patient-years, respectively. Neitherannual cardiomyopathy rate showed a steady increase,
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chronic dialysis also have a high incidence (31%) of
cardiovascular disease.
Cardiac arrhythmia was the most common cardiovas-
cular event, increasing in each subsequent annual cohort
of patients initiating dialysis from 1991 to 1994. Adoles-
cent, female, and black patients were more at risk for
the development of arrhythmia. There are no other re-
ports of arrhythmia in children with ESRD that suggest
these variables as potential risk factors. We found a
lower incidence of arrhythmia compared to the incidence
reported by Bosch et al in a group of German children
with ESRD [10]. Twenty-one (48%) of the 44 children
were on dialysis (10 PD, 11 HD). Using 24-hour EKG
monitoring, the incidence of arrhythmias in the children
on dialysis was: sinus tachycardia 57%, ventricular extra-
systoles 43%, supraventricular extrasystoles 9.5%, and
first degree atrioventricular block 9.5% [10]. Tachycardia
Fig. 3. Adjusted annual cardiomyopathy rate. most often occurred during exercise and in HD patients
following the dialysis treatment. The incidence of supra-
ventricular and ventricular extrasystole in the Bosch
study was only slightly increased above values reportedshowed a significant trend from 1991 to 1996. Overall,
to be as high as 44% in healthy children [21–23]. Our107 deaths occurred (7.4%) and cardiac deaths ac-
finding of a lower incidence of arrhythmia comparedcounted for 41 (38.3%). Overall mortality was increased
with the Bosch study is likely due to the small numberin the 0 to 4 year age group (14.6 vs. 5.6% age 5 to 9
of dialysis patients in the Bosch study (21 vs. 1454) andyears, 6.4% age 10 to 14 years, 6.2% age 15 to 19 years,
to their use of 24-hour EKG monitoring. The BoschP 0.0004) and tended to be increased for blacks (9.2 vs.
study also reported a transiently prolonged QT interval6.9% whites, 3.8% other, P  0.09), but did not differ
in 73% of the HD and 50% of the PD patients [10].significantly based on sex (7.0 male vs. 7.8% female).
In a study of 50 children with ESRD (72% on chronicThere was no significant difference in cardiac mortality
dialysis), prolongation of the QT interval was found to beby age (4.4% age 0 to 4 years, 1.4% age 5 to 9 years,
associated with duration of renal failure [24]. Although a2.2% age 10 to 14 years, 2.9% age 15 to 19 years) or
prolonged QT interval may be a risk factor for life-sex (2.6 male vs. 3.0% female). Cardiac deaths were
threatening arrhythmia in HD patients [24, 25], no poten-significantly increased among blacks (4.5 vs. 2.1% whites,
tially life-threatening arrhythmias were observed in the1.5% other, P  0.03).
pediatric ESRD patients.
To our knowledge, the incidence of valvular heart
DISCUSSION disease has not been reported in pediatric chronic dial-
ysis patients. In our study the patients with valvular heartThis is, to our knowledge, the first study to assess the
incidence and extent of cardiovascular disease in a large disease were more often in the 15- to 19-year-old age
group, female, or black. Valvular heart disease has beenpediatric chronic dialysis population. This issue has been
well addressed in adult ESRD patients [2–6]. Data on reported in adult chronic dialysis patients. Using echo-
cardiography, Maher et al found that of 87 adult patients1686 peritoneal dialysis (PD) and 1782 hemodialysis
(HD) adult patients participating in Wave 2 of the undergoing chronic HD, 28% had aortic valve calcifica-
tion, 6% aortic valve stenosis, 36% mitral annular calci-USRDS Dialysis and Morbidity and Mortality Study
showed a high prevalence of cardiovascular disease [20]. fication, and 1% mitral stenosis [25]. Aortic valvular dis-
ease and mitral annular calcification were associated withIn that prospective study, 36% of PD and 42% of HD
patients had a history of coronary artery disease, coro- an increased calcium  phosphorus product and with
a longer period of dialysis [26]. In addition to dialysisnary artery bypass surgery, coronary angioplasty or an
abnormal coronary angiogram [20]. Thirty-one percent duration, systolic hypertension, abnormal calcium and
phosphorus balance, secondary hyperparathyroidism,of PD and 40% of HD patients had prior congestive
heart failure, while 18% of PD and 22% of HD patients and elevated alkaline phosphatase levels have been
shown to be associated with the development of valvularhad evidence of left ventricular hypertrophy (LVH) on
electro- or echocardiogram [20]. Cardiomegaly on chest heart disease in dialysis patients [27–32].
The incidence of cardiomyopathy rose steadily, in-X-ray was present in 23% of PD and 29% of HD patients
[20]. In our study, we found that children undergoing creasing twofold between 1991 and 1996. Cardiomyopa-
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thy was common in all age groups ranging from 6% to artery disease may be warranted in selected pediatric
chronic dialysis patients.11%. Female sex and black race were associated with
an increased incidence of cardiomyopathy. Because the A limitation of our study was that the diagnoses were
made using ICD-9 codes from relevant claims data. Datadiagnosis of cardiomyopathy was made using ICD-9 codes
from relevant claims data, we are unable to comment used by the USRDS are provided by the Centers for
Medicare and Medicaid Services (CMS, formerly theon the specific procedural methods (that is, echocardio-
gram, electrocardiogram, chest x-ray) used to make this Health Care Financing Administration). The reliability
of USRDS data has been validated in a prior study [15].diagnosis.
Our data suggest a lower incidence of cardiomyopathy A 91% agreement rate was found between reported data
in the USRDS database and 50 variables extracted fromin pediatric chronic dialysis patients compared to the
report of Mitsnefes et al (9.6 vs. 75%) [13]. Mitsnefes on-site source documents such as medical and billing
records for 1692 selected cases [15]. Since 1996, CMSand colleagues retrospectively studied the echocardio-
graphs of 64 children aged 20 months to 22 years on has surveyed a random sample of about 10,000 dialysis
patients per year for accuracy of demographic and clini-chronic dialysis. Cardiomyopathy was defined as left ven-
tricular hypertrophy (LVH) and was present in 85% of cal variables contained in the database. The goal of these
ongoing measures is to maintain the validity of USRDSHD and 68% of PD patients. Severe LVH was associated
with low hemoglobin level, duration of dialysis, HD data. We acknowledge the inherent limitations of using
claims data; we believe our findings mandate more de-treatment, and systolic hypertension [13]. Morris et al
detected echocardiographic evidence of LVH in 12 of 13 tailed cardiovascular studies in children with ESRD.
We observed a high incidence of cardiovascular dis-(92%) anemic children on chronic dialysis with increased
severity in the patients with hypertension [33]. Johnston ease in this patient population, with cardiovascular dis-
ease accounting for the majority of known causes ofet al reported echocardiographic evidence of LVH in 3
of 10 (30%) children on chronic PD [8]. The difference death. Age, sex, and race were identified as important
prognostic variables. These variables may reflect under-in incidence of LVH between our study and that of
Morris et al is likely due to differences in patient numbers treatment or reduced access to care in these groups, and
additional studies are required to address these issues.and diagnostic techniques, and perhaps variations in the
use of diagnostic classification of cardiomyopathy (for Our findings suggest that future directions should include
example, abnormal chamber dimensions or systolic dys- improved reporting of cardiovascular events in children
function versus LVH without other findings). In addition, with ESRD, longitudinal studies of cardiovascular dis-
a prospective study actively monitoring cardiovascular ease risk factors, and a bridging of data between caregiv-
function in pediatric patients with ESRD may show a ers of pediatric and young adult patients. Much effort
higher incidence of cardiovascular disease compared to must be made to identify, treat, and prevent cardiovascu-
retrospective studies. Our incidence is consistent with lar disease and cardiovascular disease risk factors in chil-
the 9% incidence of LVH reported by Ulmer, Heupel dren with ESRD.
and Scharer in a study of 11 pediatric HD patients [34].
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